Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-label, Safety and Tolerability Trial of Obrixtamig in Combination With ZL-1310 in Patients With Poorly Differentiated NEC

NCT07707895 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07707895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07707895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-label, Safety and Tolerability Trial of Obrixtamig in Combination With ZL-1310 in Patients With Poorly Differentiated NEC
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 19, 2026
Completion date
April 26, 2030
Enrollment
60 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

extrapulmonary neuroendocrine carcinoma of large cell histology, extrapulmonary neuroendocrine carcinoma of small cell histology, large cell neuroendocrine lung carcinoma, small cell lung cancer